LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated interim data from the dose escalation phase of its Phase 1/2a clinical trial for LAVA-051, targeted at relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). This presentation will take place at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The session is scheduled for June 5, and will be led by Dr. Benjamin Winograd, LAVA's Chief Medical Officer. The trial seeks to evaluate the effectiveness of LAVA-051 as a bispecific gamma delta T-cell engager.

Positive

• Presentation of interim data at the prestigious ASCO Annual Meeting indicates progress in clinical development.
• LAVA-051 targets significant hematological malignancies, including CLL and MM, providing potential market opportunities.

Negative

• None.

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.

The details of the poster presentation session are as follows:

Abstract #: 2577
Abstract Title: Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies
Session Title: Developmental Therapeutics — Immunotherapy
Session Date: Sunday, June 5, 2022
Session Time: 8–11 a.m. CDT/9 a.m.–12 p.m. EDT
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics

About LAVA Therapeutics
LAVA Therapeutics N.V. is an immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect to the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances)    are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACTS
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

FAQ

What is the purpose of the LAVA-051 clinical trial?

The LAVA-051 trial aims to evaluate the safety and efficacy of this bispecific gamma delta T-cell engager in treating relapsed or refractory CLL and MM.

When will the interim data for LAVA-051 be presented?

The interim data will be presented during the ASCO Annual Meeting on June 5, 2022.

What are the potential implications of LAVA-051's trial results?

Positive results could lead to further development and commercialization of LAVA-051, potentially benefiting patients and the company financially.

Where can I find more information about the ongoing clinical trials for LAVA Therapeutics?

More information can be found on the LAVA Therapeutics website and the clinical trial registry under NCT04887259.